Replies to post #270402 on Anavex Life Sciences Corp (AVXL)

[Bourbon_on_my_cornflakes]

Interesting 2 real A-273 science articles show up in the last couple days.

Not MBA-type analyzts who wait for approval, but articles by those who understand the science, and think 273 has what it takes.

Nice to see sophisticated scientists vetting 273

Prove em right Dr. M.

[OFP]

but have a shot at this article:

https://finanz.dk/anavex-is-likely-to-report-positive-parkinsons-disease-trial-results-for-a2-73-increasing-share-value-nasdaqavxl/

I know people have been pointing to that article as a reason for optimism but it looks like a recent weak SA article with the same deficiencies. I read these articles discounting any general S1R effect and look for something specific to 2-73. This is because:
1. S1R agonists have been used in PDD without sufficient success to lead to an indication in the disease
2. AVXL has not shown any credible reason 2-73 should succeed where other S1Rs have failed.

Reading it without general S1R effects what's left?